CDK1 and ovarian carcinoma: A study has shown that dasatinib may enhance paclitaxel sensitivity by suppressing B cell lymphoma-2 and cyclin dependent kinase 1 expression in ovarian cancer cells via a p27(Kip1)-dependent process (34).